LIGNOSTAB-A Injection/Solution for

What is LIGNOSTAB-A

LIGNOSTAB-A is a sterile injectable solution used as a local anesthetic in medical and dental procedures. It contains a combination of Lidocaine Hydrochloride, a local anesthetic, and Adrenaline (Epinephrine), a vasoconstrictor. The lidocaine component provides rapid and effective local anesthesia by blocking nerve signals, while adrenaline prolongs the effect by constricting blood vessels at the injection site. This formulation is widely used in dentistry, minor surgical procedures, and local infiltration anesthesia.

• Active Ingredients: Lidocaine Hydrochloride 2% (20 mg/ml) and Adrenaline (typically 1:80,000 or 1:100,000)
• Pharmaceutical Form: Injectable solution in 2 ml vials
• Uses: Dental procedures, minor surgeries, nerve blocks, local infiltration
• Type: Amide-type local anesthetic with vasoconstrictor

This product is designed for professional use only and should be administered by a qualified healthcare provider.

How to use LIGNOSTAB-A

LIGNOSTAB-A is used via injection into the desired area where anesthesia is required. Only a trained medical or dental professional should administer it. The exact dosage and administration method will vary depending on the type and duration of the procedure, as well as the patient’s age, weight, and overall health.

• Route: Local infiltration or nerve block injection
• Typical Adult Dosage: 1–5 ml depending on the procedure
• Maximum Dose: Not to exceed 7 mg/kg of lidocaine; limit total adrenaline dose to 200 micrograms
• Pediatric Use: Dosage must be adjusted based on body weight and under pediatric guidance

The injection site should be aspirated before injection to avoid intravascular administration.

Mode of Action LIGNOSTAB-A

Lidocaine works by blocking sodium channels in neuronal membranes, thereby inhibiting nerve impulse propagation. This action effectively numbs the area of application, preventing the sensation of pain. Adrenaline, on the other hand, acts on alpha-adrenergic receptors in blood vessels, causing vasoconstriction. This limits systemic absorption of lidocaine, enhances the duration of anesthesia, and reduces bleeding at the site.

• Onset of Action: Rapid — typically within 1–3 minutes
• Duration: 60–120 minutes depending on the site and administration method
• Primary Effect: Local numbness and hemostasis

LIGNOSTAB-A Interactions LIGNOSTAB-A

LIGNOSTAB-A may interact with other drugs. Inform your doctor or dentist of all medications you are taking.

• Beta-blockers: May increase the effects of adrenaline on blood pressure
• Tricyclic antidepressants: May potentiate the effects of adrenaline
• Monoamine oxidase inhibitors (MAOIs): May cause hypertensive reactions when combined with adrenaline
• Antiarrhythmic drugs: Combined use with other sodium channel blockers may increase cardiac risk

Patients with cardiovascular disorders or on stimulant medications should be carefully evaluated before use.

Dosage of LIGNOSTAB-A

Dosage varies depending on the procedure and patient factors. A healthcare provider will determine the correct amount.

• Adults: Typically 1–5 ml of solution for local anesthesia
• Children: Use caution; adjust dose based on weight and procedure type
• Maximum Total Dose: Lidocaine 500 mg per procedure, adrenaline 200 mcg (consult reference guidelines)
• Frequency: Usually single administration per procedure

Repeated doses should only be administered after evaluating clinical response and toxicological risk.

Possible side effects of LIGNOSTAB-A

Most patients tolerate LIGNOSTAB-A well, but side effects may occur, particularly with overdose or intravascular injection.

• Common: Pain at injection site, mild swelling, temporary numbness
• Less Common: Restlessness, tremor, headache, dizziness
• Serious: Hypotension, bradycardia, allergic reactions, seizures, cardiac arrhythmias

Seek immediate medical attention if symptoms such as chest pain, breathing difficulty, or swelling of the face/tongue occur.

LIGNOSTAB-A Contraindications LIGNOSTAB-A

• Hypersensitivity to lidocaine, adrenaline, or other amide-type anesthetics
• Severe cardiovascular disease or uncontrolled hypertension
• Hyperthyroidism
• Pheochromocytoma
• History of severe drug reactions to local anesthetics

Use caution in patients with impaired liver function, renal impairment, or seizure disorders.

Storage of LIGNOSTAB-A

• Store below 25°C (77°F)
• Protect from light and freezing
• Keep vials in their original packaging until ready for use
• Do not use after the expiry date on the label

Always discard unused vials safely and keep away from children.